Researchers assess the cost‐effectiveness of nivolumab plus ipilimumab vs lenvatinib or sorafenib for hepatocellular carcinoma from a US healthcare payer perspective.

Researchers at Institute of Science Tokyo created a mouse model of the aggressive subtype of HCC and provided insights into its underlying molecular mechanism. Using these insights, they demonstrated ...

Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and ...

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral hepatitis, alcohol use, and obesity increase the likelihood of hepatocellular ...

Liver cancer often develops in individuals with chronic liver disease, with hepatocellular carcinoma (HCC) and cholangiocarcinoma as the main types. HCC is commonly associated with hepatitis B or C, ...

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral hepatitis, alcohol use, and obesity increase the likelihood of hepatocellular ...

Access to and Timeliness of Lung Cancer Surgery, Radiation Therapy, and Systemic Therapy in New Zealand: A Universal Health Care Context Gene fusions are critical oncogenic mutations that drive cancer ...